BioCryst’s Surging HAE Focus With Astria Therapeutics Deal
BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal valuing Astria at an implied $13.00 per share, or...
Jon Napitupulu
Assembly Biosciences to Present at Investor Conference
Assembly Biosciences will host fireside chats at two investor forums: the H.C. Wainwright Liver Disease Virtual Conference on October...
Adlai Nortye Presents on Molecular Targets at Cancer Conf.
Adlai Nortye will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on...
PMV Pharma to Present Pivotal Phase 2 Rezatapopt Results
PMV Pharmaceuticals will deliver the first look at initial data from its pivotal Phase 2 PYNNACLE study of rezatapopt...
FDA Extends Review of Denali’s Hunter Syndrome Drug
Denali Therapeutics’ biologics license application for tividenofusp alfa, a brain-penetrant enzyme replacement for Hunter syndrome (MPS II), will undergo...
PMV Pharma to Present Pivotal Phase 2 Rezatapopt Results
PMV Pharmaceuticals will present initial data from its pivotal Phase 2 PYNNACLE study of rezatapopt (PC14586), a first-in-class small...
Salarius Pharmaceuticals’ Successful Nasdaq Compliance Victory
Salarius Pharmaceuticals has regained compliance with Nasdaq’s equity standard, completing its return to full listing compliance after previously restoring...
Palisade Bio Unlocks Canadian Patent for Lead Drug Pali-2108
Palisade Bio has secured a Canadian composition-of-matter patent for PALI-2108, a gut microbiota–activated, ileocolonic-targeted PDE4 B/D inhibitor in development...
Apyx Seeks FDA Label Expansion for Liposuction System
Apyx Medical has submitted a new 510(k) to the FDA seeking a label expansion for its AYON body contouring...
Rentschler Biopharma Sees Progress on New Laupheim Facility
Rentschler Biopharma is building a new buffer media station at its Laupheim, Germany headquarters, the largest single investment the...